More Than Skin Deep: Bringing Precision Medicine to Systemic Sclerosis

Affiliations

Editorial

Christopher A Mecoli et al. Arthritis Rheumatol. 2020 Mar.

. 2020 Mar;72(3):383-385.

doi: 10.1002/art.41154. Epub 2020 Jan 30.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no relevant conflicts of interest to disclose.

1. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29:255–73. - PubMed
1. Hamaguchi Y Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42–53. - PubMed
1. Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. Arthritis Rheumatol. 2015;67:3234–44. - PubMed
1. Cottrell TR, Wise RA, Wigley FM, Boin F. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis. 2014;73:1060–6. - PMC - PubMed
1. Walker JG, Steele RJ, Schnitzer M, Taillefer S, Baron M. Canadian Scleroderma Research Group, Hudson M. The association between disease activity and duration in systemic sclerosis. J Rheumatol. 2010;37:2299–306. - PubMed